LATE-STAGE DEVELOPMENT
How will your agent perform in the market when it launches? And how will that change as the paradigm evolves?
For assets in late-stage development, competitive advantage and timing is everything. Our framework allows for dynamic time-series forecasting in order predict the share of an asset, as well as that of each of its competitors.
Patient Share Forecasting
For teams in late-stage development, we seamlessly integrate our “Competition Module” with our DTA technology to forecast patient share over time.
The forecast functionality of our “Competition Module” takes into account the clinical attributes of the user’s TPP along with that of its competitors and each asset’s launch timing in order to forecast quarterly share and provide insight into how different agents will compete with each other in the market.
These models allow users to instantly revise patient share and revenue predictions when fresh information arises about an asset’s clinical attributes and launch date, or as new information emerges about competitors—allowing teams to quickly and authoritatively answer management questions about the impact of events.
Epidemiology and Patient Flow Modelling
To support revenue projections, we can provide well-sourced and carefully-curated epidemiology estimates in our forecast models.
In addition, we also offer bespoke incidence-based patient-flow models and epidemiology forecasts that accurately estimate the number of patients available for treatment at each stage of disease and line of treatment.
Market access
Our market access analytics can be used for both early and late-stage assets. We compare the clinical benefit of the drug to its cost, and benchmark those results to a historical data set of launched drugs to identify appropriate analogs. Our clinical benefit vs. cost metric is strongly predictive of the pricing and market access outlook for new agents.
Oncology TPP Predictor
Equinox Group has developed a proprietary oncology-focused endpoints database, spanning over 30,000 drug regimens. It has the analytical power to project likely OS outcomes for a given TPP with known PFS, based on drug characteristics such as tumor type and mechanism.
